--- schema_version: "secwatch.filing_event.v1" accession: "0001104659-25-119680" form_type: "8-K" ticker: "APRE" cik: "0001781983" company_name: "Aprea Therapeutics, Inc." filed_at: "2025-12-09T23:59:59+00:00" generated_at: "2026-05-16T13:48:56.400564+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.65 calibrated_materiality_score: 0.65 confidence: "high" source: SEC EDGAR --- # Aprea Therapeutics raises $3.1M in private placement priced at $1.165/unit ## Summary - Gross proceeds ~$3.1M from 2.62M shares (or pre-funded warrants) and warrants at $1.04 exercise price. - Combined effective price $1.165 per unit; warrants exercisable for 5 years. - Net proceeds to extend cash runway into Q1 2027; closing expected December 10, 2025. - Maxim Group LLC sole placement agent; receives 7% fee and 257,510 placement agent warrants. - Includes participation from new and existing healthcare investors and insiders. ## SEC filing metadata - accession: 0001104659-25-119680 - form_type: 8-K - ticker: APRE - cik: 0001781983 - company_name: Aprea Therapeutics, Inc. - filed_at: 2025-12-09T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.65 - calibrated_materiality_score: 0.65 - confidence: high - sec_items: 1.01, 3.02, 7.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465925119680/0001104659-25-119680-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465925119680/tm2533057d1_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001104659-25-119680 - JSON: https://secwatch.observer/filing/0001104659-25-119680.json - Plain text: https://secwatch.observer/filing/0001104659-25-119680.txt ## Key facts - Equity Issuances Aprea Therapeutics, Inc. issued 2,623,023 shares of common stock to accredited investors and Company insiders for combined effective offering price of $1.165 per share, expected aggregate gross proceeds at closing of approximately $3.1 million. - Security: common stock - Shares: 2,623,023 shares - Purchaser: accredited investors and Company insiders - Consideration: combined effective offering price of $1.165 per share, expected aggregate gross proceeds at closing of approximately $3.1 million source text: and together with the Pre-Funded Warrants, the “Warrants”). The combined effective offering price of each Private Placement Share and accompanying Common Warrant to be issued is $1.165 and represents the “Minimum Price” in accordance with Nasdaq Listing Rule 5635(d), for expected aggregate gross proceeds at closing of approximately $3.1 million. The closing of evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465925119680/0001104659-25-119680-index.htm - Material Agreements Aprea Therapeutics, Inc. entered into Purchase Agreement with certain accredited investors and Company insiders valued at approximately $3.1 million (effective 2025-12-08). - Action: entry - Agreement: equity purchase - Counterparty: certain accredited investors and Company insiders - Value: approximately $3.1 million - Effective: 2025-12-08 source text: On December 8, 2025, Aprea Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors and Company insiders (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 2,623,023 shares (the “Private Placement Shares”) of the Company’s Common Stock, par value $0.001 per share (“Common Stock”) or pre-funded Common Stock purchase warrants (the “Pre-Funded Warrants”) in lieu thereof, and (ii) common stock purchase warrants to purchase up to 2,623,023 shares of Common Stock (the “Warrant Shares”) at an exercise price of $1.04 per share (the “Common Warrants” and together with the Pre-Funded Warrants, the “Warrants”). evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465925119680/0001104659-25-119680-index.htm - Material Agreements Aprea Therapeutics, Inc. entered into Placement Agency Agreement with Maxim Group LLC (effective 2025-12-08). - Action: entry - Agreement: underwriting - Counterparty: Maxim Group LLC - Effective: 2025-12-08 source text: On December 8, 2025, and in connection with the Purchase Agreement, the Company entered into a customary placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (“Maxim”). evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465925119680/0001104659-25-119680-index.htm - Material Agreements Aprea Therapeutics, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2025-12-08). - Action: entry - Agreement: equity purchase - Counterparty: the Purchasers - Effective: 2025-12-08 source text: In connection with the Private Placement, the Company and the Purchasers entered into a Registration Rights Agreement, dated December 8, 2025 (the “Registration Rights Agreement”), providing for the registration for resale of Private Placement Shares along with the shares of Common Stock underlying the Pre-Funded Warrants, and Common Warrants that are not then registered on an effective registration statement, pursuant to a registration statement (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “SEC”) on or prior to the 20 th day after the Closing Date. evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465925119680/0001104659-25-119680-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.